Article
[Fcγ receptorIIIa polymorphism in healthy children and those with hematological malignancies].
Zhongguo shi yan xue ye xue za zhi - 1 Aug 2010
Qu Yu-Hua, Li Yang, Wu Yan-Feng, Fang Jian-Pei, Wei Jing, Huang Shao-Liang, Ma Xiao-Xiao, Huang Yan
Abstract excerpt
Fcγ receptorIIIa (FcγRIIIa) polymorphism was considered to influence clinical response to therapeutic monoclonal antibody (MAb) against cancer, which is suggested to affect MAb binding and MAb-dependent NK cell-mediated cytotoxicity. The purpose of this study was to examine the FcγRIIIa gene polymorphisms in healthy children and in children with hematological malignancy, and to explore its possible effect on MAb...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
